<DOC>
	<DOCNO>NCT00343083</DOCNO>
	<brief_summary>The purpose study evaluate response tumor treatment regimen use study . This study also test safety cetuximab ( C225 ) , give chemotherapy radiation therapy . We also want see effect ( good bad ) cetuximab , chemotherapy , radiation therapy head &amp; neck cancer . C225 design stop growth tumor block certain chemical pathway lead tumor cell growth . In prior study head &amp; neck cancer patient , C225 delay tumor growth provide relief symptom patient .</brief_summary>
	<brief_title>Evaluation Cetuximab ( ERBITUX ) Concurrent Carboplatin , Paclitaxel &amp; Radiotherapy Management Patients With Advanced Locoregional Squamous Cell Carcinomas Head Neck ( GCC 0442 )</brief_title>
	<detailed_description>Primary Objective- To evaluate whether addition Cetuximab ( C225 ) combination chemotherapy radiation cause enhance anti-tumor effect result improve local regional control patient locally advance , unresectable squamous cell carcinoma head neck . ( SCCHN ) . OVERVIEW OF STUDY DESIGN Open label , non-randomized , single arm trial . P = Paclitaxel administer weekly schedule dose 40mg/m2 IV 1-hour infusion prior cetuximab dose . This administer total 8 week ( week 2-9 ) C225 = Cetuximab : 400 mg/m2 IV give initial OR load dose week 1 250 mg/m2 IV weekly give 8 week ( week 2-9 ) . C = Carboplatin give dose AUC=2/week - administer 30 minute infusion cetuximab infusion ( week 2-9 ) RT = Radiation therapy deliver 1.8 Gy fraction/day , 5 day week total 70.2 Gy . RT give week 2-9 . Note : Sequence administration paclitaxel follow cetuximab follow carboplatin follow XRT . Approximately 60 patient MSGCC/BVAMC participate study . Prior enter study doctor examine patient order blood test ( do blood draw , approximately 2 tablespoon ) test measure patient disease ( scan ) . The patient also evaluate dietician follow patient throughout course therapy help patient meet his/her nutritional need</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Histologically prove locally advanced squamous cell carcinoma head neck primary site . The following TNM stage sit eligible.Oral cavity , Pharynx , Larynx , Nasopharynx , paranasal sinus , Oral cavity , Pharynx , Larynx , Nasopharynx , paranasal sinus T4 N0 N1 N2A , B , C N3 , T3 N0 N1 N2A , B , C N3 Any T N2A , B , C N3 Unknown primary Tx N2A , B , C N3 Note : Only clearly unresectable T4 N0 lesion eligible study provide reason unresectability due extensive anatomic involvement outline surgeon 2 . Patients must sign approve informed consent . 3 . Patients Performance Status 02 . 4 . No evidence distant metastatic disease . 5 . No previous radiation therapy . 6 . No previous chemotherapy . 7 . Patients must great 18 year age . 8 . Women child bear potential ( WOCBP ) must negative pregnancy test within 7 day treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . 9 . Pretreatment evaluation include : History physical examination within four week prior study entry Dental evaluation Medical oncology examination evaluate medical contraindication prior start chemotherapy 10 . Adequate renal &amp; bone marrow function determine follow laboratory parameter : ANC great equal 1500/mm3 ; platelet great equal 100,000/mm3 ; hemoglobin great equal 8.0 g/dl ; Serum Creatinine less equal 2.0 mg/dl , Total bilirubin le 1.5 X ULIN ; AST/ALT le 3 time ULN , Creatinine Clearance great equal 50 cc/min 11 . Evidence measurable disease . 12 . No evidence concomitant malignancy except nonmelanomatous skin cancer ( control controllable ) carcinoma situ cervix . Any following criterion make patient ineligible participate study : 1 . Acute hepatitis know HIV . 2 . Active uncontrolled infection . 3 . Significant history concomitant life threaten / uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , know cardiomyopathy decrease ejection fraction , cardiac arrhythmia 4 . Prior therapy specifically directly target EGFR pathway . 5 . Prior severe infusion reaction monoclonal antibody . 6 . Any concurrent chemotherapy indicate study protocol investigational agent ( ) . 7 . Women childbearing potential ( WOCBP ) male participant unwilling unable use effective method avoid pregnancy entire study period 8 . Preexisting clinically significant neuropathy . 9 . Patients locoregional recurrence site prior radiation therapy amenable salvage surgery eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Head Neck Neoplasms</keyword>
</DOC>